Compare SNFCA & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNFCA | CGEN |
|---|---|---|
| Founded | 1965 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 188.2M |
| IPO Year | 1995 | 2001 |
| Metric | SNFCA | CGEN |
|---|---|---|
| Price | $9.66 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 28.5K | ★ 485.8K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.51 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $344,587,538.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $7.67 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $7.70 | $1.23 |
| 52 Week High | $11.00 | $3.24 |
| Indicator | SNFCA | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 59.14 |
| Support Level | $9.50 | $1.45 |
| Resistance Level | $9.78 | N/A |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 40.91 | 53.93 |
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.